FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154182502> ?p ?o ?g. }

• W3154182502 abstract "Gemtuzumab ozogamicin (GO) administered before allogeneic hematopoietic cell transplantation (alloHCT) has been linked to an increased risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).This retrospective analysis examined VOD/SOS risk and clinical outcomes in pediatric patients with acute myeloid leukemia who received myeloablative alloHCT in 2008-2011 with (n = 148) and without (n = 348; controls) prior GO exposure and were reported to the Center for International Blood and Marrow Transplant Research.Cumulative incidences (95% confidence interval [CI]) of VOD/SOS and severe VOD/SOS, respectively, at 100 days were 16% (11-23%) and 8% (4-13%) for GO-exposed patients and 10% (7-13%) and 3% (2-5%) for controls. With a median follow-up of approximately 7 years, the 5-year adjusted overall survival probability (95% CI) after alloHCT was 51% (43-58%) and 55% (50-60%) for GO-exposed patients and controls, respectively; three (4%) and one (<1%) deaths were attributed to VOD/SOS. In multivariate analyses, GO exposure was observed to be associated with an increased risk of VOD/SOS at 100 days, but was not associated with overall survival, disease-free survival, relapse, or nonrelapse mortality.Results suggest that GO treatment prior to alloHCT in pediatric patients may increase the risk of VOD/SOS but not death." @default.
• W3154182502 created "2021-04-26" @default.
• W3154182502 creator A5009654984 @default.
• W3154182502 creator A5042986170 @default.
• W3154182502 creator A5043585238 @default.
• W3154182502 creator A5046048880 @default.
• W3154182502 creator A5058862489 @default.
• W3154182502 creator A5059161986 @default.
• W3154182502 creator A5069809093 @default.
• W3154182502 creator A5072480385 @default.
• W3154182502 creator A5084043008 @default.
• W3154182502 date "2021-04-19" @default.
• W3154182502 modified "2023-10-18" @default.
• W3154182502 title "Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation" @default.
• W3154182502 cites W1492609361 @default.
• W3154182502 cites W1558704041 @default.
• W3154182502 cites W1779344217 @default.
• W3154182502 cites W1821781403 @default.
• W3154182502 cites W1966771497 @default.
• W3154182502 cites W1977455450 @default.
• W3154182502 cites W1993078113 @default.
• W3154182502 cites W1993783426 @default.
• W3154182502 cites W2008748351 @default.
• W3154182502 cites W2025338891 @default.
• W3154182502 cites W2037010003 @default.
• W3154182502 cites W2051239881 @default.
• W3154182502 cites W2054634308 @default.
• W3154182502 cites W2075766764 @default.
• W3154182502 cites W2107943299 @default.
• W3154182502 cites W2107968021 @default.
• W3154182502 cites W2117550229 @default.
• W3154182502 cites W2137881702 @default.
• W3154182502 cites W2151475548 @default.
• W3154182502 cites W2152197116 @default.
• W3154182502 cites W2169923083 @default.
• W3154182502 cites W2396687607 @default.
• W3154182502 cites W2487244003 @default.
• W3154182502 cites W2793137791 @default.
• W3154182502 cites W2809534462 @default.
• W3154182502 cites W2910888855 @default.
• W3154182502 cites W2998104581 @default.
• W3154182502 cites W3127939395 @default.
• W3154182502 cites W65526502 @default.
• W3154182502 doi "https://doi.org/10.1002/pbc.29067" @default.
• W3154182502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8324076" @default.
• W3154182502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33871892" @default.
• W3154182502 hasPublicationYear "2021" @default.
• W3154182502 type Work @default.
• W3154182502 sameAs 3154182502 @default.
• W3154182502 citedByCount "2" @default.
• W3154182502 countsByYear W31541825022022 @default.
• W3154182502 countsByYear W31541825022023 @default.
• W3154182502 crossrefType "journal-article" @default.
• W3154182502 hasAuthorship W3154182502A5009654984 @default.
• W3154182502 hasAuthorship W3154182502A5042986170 @default.
• W3154182502 hasAuthorship W3154182502A5043585238 @default.
• W3154182502 hasAuthorship W3154182502A5046048880 @default.
• W3154182502 hasAuthorship W3154182502A5058862489 @default.
• W3154182502 hasAuthorship W3154182502A5059161986 @default.
• W3154182502 hasAuthorship W3154182502A5069809093 @default.
• W3154182502 hasAuthorship W3154182502A5072480385 @default.
• W3154182502 hasAuthorship W3154182502A5084043008 @default.
• W3154182502 hasBestOaLocation W31541825022 @default.
• W3154182502 hasConcept C10205521 @default.
• W3154182502 hasConcept C126322002 @default.
• W3154182502 hasConcept C141071460 @default.
• W3154182502 hasConcept C176290653 @default.
• W3154182502 hasConcept C2777408962 @default.
• W3154182502 hasConcept C2778623314 @default.
• W3154182502 hasConcept C2778729363 @default.
• W3154182502 hasConcept C2780895475 @default.
• W3154182502 hasConcept C28328180 @default.
• W3154182502 hasConcept C2911091166 @default.
• W3154182502 hasConcept C44249647 @default.
• W3154182502 hasConcept C54355233 @default.
• W3154182502 hasConcept C71924100 @default.
• W3154182502 hasConcept C86803240 @default.
• W3154182502 hasConceptScore W3154182502C10205521 @default.
• W3154182502 hasConceptScore W3154182502C126322002 @default.
• W3154182502 hasConceptScore W3154182502C141071460 @default.
• W3154182502 hasConceptScore W3154182502C176290653 @default.
• W3154182502 hasConceptScore W3154182502C2777408962 @default.
• W3154182502 hasConceptScore W3154182502C2778623314 @default.
• W3154182502 hasConceptScore W3154182502C2778729363 @default.
• W3154182502 hasConceptScore W3154182502C2780895475 @default.
• W3154182502 hasConceptScore W3154182502C28328180 @default.
• W3154182502 hasConceptScore W3154182502C2911091166 @default.
• W3154182502 hasConceptScore W3154182502C44249647 @default.
• W3154182502 hasConceptScore W3154182502C54355233 @default.
• W3154182502 hasConceptScore W3154182502C71924100 @default.
• W3154182502 hasConceptScore W3154182502C86803240 @default.
• W3154182502 hasFunder F4320307765 @default.
• W3154182502 hasFunder F4320332175 @default.
• W3154182502 hasFunder F4320337345 @default.
• W3154182502 hasIssue "8" @default.
• W3154182502 hasLocation W31541825021 @default.
• W3154182502 hasLocation W31541825022 @default.
• W3154182502 hasLocation W31541825023 @default.
• W3154182502 hasOpenAccess W3154182502 @default.
• W3154182502 hasPrimaryLocation W31541825021 @default.

• next